Pure Global
NCT03148210

Undiagnosed COPD and Asthma Population Study (UCAP)

A Randomized, Controlled, Clinical Trial to Address the Burden of Undiagnosed Airflow Obstruction in Canadian Adults
Ottawa Hospital Research Institute·ClinicalTrials.gov·drugActive, not recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Asthma,COPD
Drug/Device/Intervention
Treatment strategy using evidence-based guidelines for asthma or COPD
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ottawa Hospital Research Institute
Location
Calgary,Edmonton,Vancouver,Winnipeg,Saint John's,Halifax,Hamilton,Kingston,London,Ottawa,Toronto,Montreal,Montréal,Québec City,Saskatoon, Canada
Timeline & enrollment
Phase
N/A
Start date
Jun 05, 2017
End date
Jan 13, 2024
Enrollment
508 participants
Primary outcome

Annual rate of patient initiated healthcare utilization events for respiratory illness

Summary

Previous population health studies suggest that up to 10% of Canadian adults have undiagnosed
 asthma or COPD- these people are currently undiagnosed and untreated, even though they may
 have significant respiratory symptoms. Our study will use targeted casefinding to find people
 with undiagnosed asthma and COPD in Canadian communities. The investigators will assess their
 symptoms and their health care use and number of sick days to determine the burden of
 undiagnosed respiratory disease in these people. The investigators will then determine
 whether early treatment of previously undiagnosed airflow obstruction will improve patients'
 health outcomes.

ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaOther chronic obstructive pulmonary disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03148210
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03148210 through Pure Global AI's free database. This phase not specified trial is sponsored by Ottawa Hospital Research Institute and is currently Active, not recruiting. The study focuses on Asthma,COPD. Target enrollment is 508 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.